Citations

Clear

421 citation(s) found for "Short, C".

Short Communication: HIV VprR77Q Mutation Does Not Influence Clinical Response of Individuals Initiating Highly Active Antiretroviral Therapy
Chui, Celia, Cheung, Peter K. , Brumme, Chanson J. , Mo, Theresa, Brumme, Zabrina L. , Montaner, Julio , Badley, Andrew D. , Harrigan, P. Richard , Badley, Andrew D

Mayo Clinic

AIDS Research and Human Retroviruses | July 10, 2006 | Volume: 22 | Issue: 7 | Pages: 615-618

10.1089/aid.2006.22.615 | PMID 16831085 Get It

Teduglutide for the Treatment of Short Bowel Syndrome
Ferrone, Marcus , Scolapio, James S.

Mayo Clinic

Annals of Pharmacotherapy | May 16, 2006 | Volume: 40 | Issue: 6 | Pages: 1105-1109

10.1345/aph.1g419 | PMID 16705029 Get It

Objective: To summarize the pharmacology, development, and clinical application of teduglutide (ALX-0600), a glucagon-like peptide-2 (GLP-2) analog for the treatment of short bowel syndrome (SBS). Data Sources: Clinical literature, including both primary sources and review articles, was accessed through a search of the MEDLINE databases (1980–March 2006). Key search terms included teduglutide, ALX-0600, glucagon-like peptide-2, short bowel syndrome, short gut, and intestinal adaptation. Clinical trial and drug data were supplied by the manufacturer, NPS Pharmaceuticals. Study Selection and Data Extraction: Review articles, abstracts, and clinical studies related to GLP-2 and its analog, teduglutide, were analyzed. An evaluation of the research exploring teduglutide for the management of SBS was conducted. Relevant information was then selected. Data Synthesis: Research has revealed that administration of GLP-2 to patients following major small bowel resection improves intestinal adaptation and nutrient absorption. Teduglutide is an enzyme-resistant GLP-2 analog that shows promise in preventing intestinal injury, restoring mucosal integrity, and enhancing intestinal absorptive function. Conclusions: Data from ongoing clinical trials indicate that teduglutide may have the ability to enhance intestinal absorptive capacity in patients with SBS. Further studies and the completion of Phase III trials are necessary to determine the appropriate dosage and length of treatment for patients with SBS to gain optimal therapeutic benefit from this drug.
Cluster Headache with Short-Lived Visual Symptoms
Fattah, QA, Cutrer, F. Michael

Mayo Clinic

Cephalalgia | March 23, 2006 | Volume: 26 | Issue: 4 | Pages: 492-493

10.1111/j.1468-2982.2006.01052.x | PMID 16556254 Get It

Biochemical and Electrochemical Characterization of Two Variant Human Short-Chain Acyl-CoA Dehydrogenases
Saenger, Amy K., Nguyen, Tien V., Vockley, Jerry , Stankovich, Marian T., Nguyen, Tien V.

Mayo Clinic

Biochemistry | December 6, 2005 | Volume: 44 | Issue: 49 | Pages: 16035-16042

10.1021/bi051049q | PMID 16331963 Get It

Thermodynamic Regulation of Human Short-Chain Acyl-CoA Dehydrogenase by Substrate and Product Binding
Saenger, Amy K., Nguyen, Tien V., Vockley, Jerry , Stankovich, Marian T., Nguyen, Tien V.

Mayo Clinic

Biochemistry | December 6, 2005 | Volume: 44 | Issue: 49 | Pages: 16043-16053

10.1021/bi051048y | PMID 16331964 Get It

Short-Course Regimens of Artesunate-Fosmidomycin in Treatment of Uncomplicated Plasmodium falciparum Malaria
Borrmann, Steffen , Adégnika, Ayôla Akim , Moussavou, Félicien, Oyakhirome, Sunny, Esser, Gilbert, Matsiegui, Pierre‐Blaise, Ramharter, Michael , Lundgren, Ingrid, Kombila, Maryvonne, Issifou, Saadou, Wiesner, Jochen, Jomaa, Hassan, Hutchinson, David K. , Kremsner, Peter G.

Mayo Clinic

Antimicrobial Agents and Chemotherapy | August 26, 2005 | Volume: 49 | Issue: 9 | Pages: 3749-3754

10.1128/aac.49.9.3749-3754.2005 | PMID 16127049 Get It

ABSTRACT Fosmidomycin is effective against malaria, but it needs to be given for ≥4 days when used alone. We conducted a study of 50 children with Plasmodium falciparum malaria to evaluate the safety and efficacy of consecutively shortened regimens of artesunate-fosmidomycin (1 to 2 mg/kg of body weight and 30 mg/kg of body weight, respectively; doses given every 12 hours). All dosing regimens were well tolerated. Artesunate-fosmidomycin acted rapidly, resulting in consolidated geometric mean parasite and fever clearance times of 24 h and 15 h, respectively. Treatment regimens of ≥2 days led to cure ratios of 100% by day 14 (39/39; 95% confidence interval [95% CI], 91% to 100%). Most importantly, the 3-day regimen achieved 100% cure on day 28 (10/10; 95% CI, 69% to 100%). Treatment with artesunate-fosmidomycin was associated with transient grade I or II neutropenia (absolute neutrophil counts of 750 to 1,200/μl and 400 to 749/μl, respectively) in six or two patients, respectively. Artesunate-fosmidomycin demonstrates the feasibility and potential value of short-course artemisinin-based combination chemotherapy with rapidly eliminated combination partners.
The Distal Short Consensus Repeats 1 and 2 of the Membrane Cofactor Protein CD46 and Their Distance from the Cell Membrane Determine Productive Entry of Species B Adenovirus Serotype 35
Fleischli, Christoph, Verhaagh, Sandra, Havenga, Menzo , Sirena, Dominique, Schaffner, Walter, Cattaneo, Roberto , Greber, Urs F. , Hemmi, Silvio

Mayo Clinic

Journal of Virology | July 13, 2005 | Volume: 79 | Issue: 15 | Pages: 10013-10022

10.1128/jvi.79.15.10013-10022.2005 | PMID 16014961 Get It

ABSTRACTThe human regulator of complement activation membrane cofactor protein (CD46) has recently been identified as an attachment receptor for most species B adenoviruses (Ads), including Ad type 3 (Ad3), Ad11, and Ad35, as well as species D Ad37. To characterize the interaction between Ad35 and CD46, hybrid receptors composed of different CD46 short consensus repeat (SCR) domains fused to immunoglobulin-like domains of CD4 and a set of 36 CD46 mutants containing semiconservative changes of single amino acids within SCR domains I and II were tested in binding and in Ad35-mediated luciferase transduction assays. In addition, anti-CD46 antibodies and soluble polypeptides constituting various CD46 domains were used in binding inhibition studies. Our data indicate that (i) CD46 SCR I or SCR II alone confers low but significant Ad35 binding; (ii) the presence of SCR I and II is required for optimal binding and transgene expression; (iii) transduction efficiencies equivalent to that of full-length CD46 are obtained if SCR I and II are at an appropriate distance from the cell membrane; (iv) ablation of the N-glycan attached to SCR I has no influence on receptor function, whereas ablation of the SCR II N-glycan results in about a two- to threefold reduction of binding and transgene expression; (v) most putative Ad35 binding residues are located on the same solvent-exposed face of the SCR I or SCR II domain, which are twisted by about 90°; and (vi) the putative Ad35 binding sites partly overlap with the measles virus binding surface.
Decline in skeletal muscle mitochondrial function with aging in humans
Short, Kevin R. , Bigelow, Maureen L., Kahl, Jane, Singh, Ravinder, Coenen-Schimke, Jill M., Raghavakaimal, Sreekumar, Nair, K. Sreekumaran

Mayo Clinic

Proceedings of the National Academy of Sciences | March 30, 2005 | Volume: 102 | Issue: 15 | Pages: 5618-5623

10.1073/pnas.0501559102 | PMID 15800038 Get It

Cumulative mtDNA damage occurs in aging animals, and mtDNA mutations are reported to accelerate aging in mice. We determined whether aging results in increased DNA oxidative damage and reduced mtDNA abundance and mitochondrial function in skeletal muscle of human subjects. Studies performed in 146 healthy men and women aged 18–89 yr demonstrated that mtDNA and mRNA abundance and mitochondrial ATP production all declined with advancing age. Abundance of mtDNA was positively related to mitochondrial ATP production rate, which in turn, was closely associated with aerobic capacity and glucose tolerance. The content of several mitochondrial proteins was reduced in older muscles, whereas the level of the oxidative DNA lesion, 8-oxo-deoxyguanosine, was increased, supporting the oxidative damage theory of aging. These results demonstrate that age-related muscle mitochondrial dysfunction is related to reduced mtDNA and muscle functional changes that are common in the elderly.
Effect of Short-Term Prednisone Use on Blood Flow, Muscle Protein Metabolism, and Function
Short, Kevin R. , Bigelow, Maureen L., Nygren, Jonas , Nair, K. Sreekumaran

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | December 3, 2004 | Volume: 89 | Issue: 12 | Pages: 6198-6207

10.1210/jc.2004-0908 | PMID 15579778 Get It

Duplication of 7p: Further delineation of the phenotype and restriction of the critical region to the distal part of the short arm
Berry, Susan A. , Dewald, Gordon W., King, Richard A. , Reish, Orit

Mayo Clinic

American Journal of Medical Genetics | October 20, 2004 | Volume: 61 | Issue: 1 | Pages: 21-25

10.1002/(sici)1096-8628(19960102)61:1<21::aid-ajmg4>3.0.co;2-# | PMID 8741912 Get It